CalciMedica, Inc.
CALCHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, CalciMedica, Inc. (CALC) is listed under Biotechnology. The company carries a $8.4M market cap, placing it firmly in the micro-cap category. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Market Cap
$8.4M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-0.75
EPS (TTM)
$-7.33
EPS (Fwd)
$-1.63
ROE
-365.7%
ROA
-63.6%
Cash
$18.6M
Total Debt
$9.2M
Free CF
-$10.5M
52W Change
-91.8%
Annual Financials
Cash vs Debt
Where CALC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CALC finished 67.31% below its 150-day moving average ($3.12) and 80.61% below its 200-day moving average ($5.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CALC overbought or oversold?
At the October 20, 2026 close, CALC's RSI(14) was 7.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $18.6M in cash and $9.2M in debt, CALC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$10.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -365.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, CALC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CALC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.